MariMed Q2 FY26 GAAP net loss widens to $3.6 million; revenue rises 6.12% to $41.9 million
MRMD•Management commentary
CEO Jon Levine cited sequential gains in wholesale and retail revenue, positive operating cash flow, and continued focus on “Expand the Brand” growth.
Q2 revenue and profitability trends
- MariMed posted Q2 revenue of $41.9 million, up 6.12% year over year, marking its highest quarterly revenue.
- Net loss widened to $3.6 million from $1.4 million; operating income slipped to $418,000 from $1.02 million.
- GAAP gross margin fell 1.6 percentage points to 38.7%.
- Non-GAAP adjusted EBITDA declined to $3.95 million from $4.79 million.
